Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Humabs BioMed, the Institute for Research in Biomedicine (IRB), and the UK Medical Research Council (MRC) have collaborated to discover a novel, proprietary monoclonal antibody (FI6).
Subscribe to our email newsletter
FI6 is a neutralizing antibody which binds and neutralizes both Group 1 and Group 2 human and animal influenza A viruses.
The researchers were able to culture single plasma cells in vitro, and screen plasma cells to isolate the rare ones which produced an antibody of unique specificity, by using the Humabs’ proprietary technology platform.
Humabs is in discussions with potential partners to take the antibody into the next stage of development.
Humabs CSO and IRB director Antonio Lanzavecchia said FI6 represents an important new treatment option and they look forward to take it through to the next stage of development.
"Furthermore, our proprietary antibody isolation platform is delivering a number of high quality preclinical, antibodies and we are building a pipeline in infectious and inflammatory diseases," Lanzavecchia said.